Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: JAMA Oncol. 2015 Jul;1(4):486–494. doi: 10.1001/jamaoncol.2015.1432

Figure 1. ADAMTS Mutations in the Cancer Genome Atlas (TCGA) Discovery Cohort.

Figure 1

ADAMTS and BRCA1 or BRCA2 mutations that were detected in the 210 TCGA patients with ovarian cancer in the discovery cohort. A, For each gene (row) indicated, tumors (columns) with mutations are labeled with red (nonsilent mutations), dark blue (silent mutations), or light blue (germline mutations) bars. The locations of the residuals altered by ADAMTS mutations are detailed in eFigure 3 in the Supplement. B, Chemotherapy response status and clinicopathologic characteristics for each individual patient. “Without residual” denotes a tumor with no macroscopic disease. The P values show the comparison between the ADAMTS-mutated cases vs ADAMTS wild-type cases. C, Mutation count for each individual gene shown in panel A.